• Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog
Trout Creek VENTURES
  • Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog

BLOG

ProNAi Therapeutics on deck for IPO

7/7/2015

0 Comments

 
  • Vancouver, British Columbia, Canada-based ProNAi Therapeutics(Pending:DNAI) is set for its IPO of 6.7M shares of common stock at $14 – 16.
  • The clinical stage biotech develops cancer therapeutics based on its proprietary DNA interference (DNAi) technology. Its lead product candidate is PNT2258, which targets an oncogene that plays a key role in programmed cell death (apoptosis) called BCL2. In a recent Phase 2 study, the disease control rate (DCR) in patients with relapsed/refractory non-Hodgkin’s lymphoma who received PNT2258 was 85% (n=11/13). DCR includes complete responses, partial responses and stable (not progressing) disease). In addition, all four patients with diffuse large B-cell lymphoma who received PNT2258 experienced a clinical response, including three complete responses.
  • 2014 Financials ($M): Operating Expenses: 22.6 (+463.7%); Net Loss: (73.7) (-487.7%); Cash Burn: (21.8) (-509.9%).
​
This entry was posted in ProNAi. Bookmark the permalink.

0 Comments



Leave a Reply.

    TROUT CREEK VENTURes

    A regional co-investment fund specializing in angel and early stage private equity.

    Archives

    June 2017
    March 2017
    November 2016
    September 2016
    July 2016
    April 2016
    March 2016
    February 2016
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    December 2014
    November 2014
    October 2014
    August 2014
    June 2014
    May 2014
    April 2014
    February 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    February 2013
    January 2013
    December 2012
    October 2012
    September 2012
    August 2012
    July 2012
    May 2012
    March 2012
    June 2010

    Categories

    All
    Ambiq Micro
    News

    RSS Feed

Picture

HOME

PHILOSOPHY

PORTFOLIO

TEAM

BLOG

Copyright © 2017 Trout Creek Ventures. All Rights Reserved.​
  • Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog